RARE News and Press, Ultragenyx Pharmaceutical Inc. From 04/27/23

NOVATO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at ...

2023-04-23 00:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The bank tsunami that ...

NOVATO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the ...

2023-03-14 08:51:59 ET Ultragenyx Pharmaceutical ( NASDAQ: RARE ) promotes Eric Crombez to Chief Medical Officer and executive Vice President succeeding Camille Bedrosian, effective May 1, 2023 Camille Bedrosian will remain with the company in a full-ti...

NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company i...

NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the c...

Summary Mereo and Ultragenyx are collaborating to develop setrusumab, a sclerostin inhibitor, for treating patients with Osteogenesis Imperfecta. ASTEROID Phase 2 trial showed that setrusumab improved bone markers and density, and strength but not patient-reported outcomes or fracture r...

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2022 Earnings Conference Call Feb 16, 2023, 05:00 PM ET Company Participants Joshua Higa - Head of Investor Relations Emil Kakkis - Founder, President and Chief Executive Officer Erik Harris - Executive Vice President and Chief ...

Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q4 GAAP EPS of -$2.16 beats by $0.02 . Revenue of $103.35M (+23.9% Y/Y) misses by $1.76M . 2023 expected Total Revenue guidance between $425 million to $450 million vs $426.25M consensus, Crysvita revenue of $...

2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita ® revenue of $ 279.4 million and Dojolvi ® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 mill...